The firm will assess whether adding its CD33-targeted radiotherapy Actimab-A to PD-1 inhibitors will benefit patients more than PD-1 inhibitors alone.
Actinium Pharmaceuticals (ATNM) announced a clinical program comprising of trials studying Actimab-A in combination with either Keytruda – ...
MedPage Today on MSN21h
Better Response, Survival in Head and Neck Cancer With Dual Pre-Op ImmunotherapyTwo neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced a clinical program comprising of trials ...
During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, discussed trials of targeted agents for EGFR-mutant lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback